Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

European Coronavirus Planning Requires ‘Structured Dialog’

Stakeholders Forum Is Urgently Needed To Plan For Extended Outbreak

Executive Summary

European off-patent industry association Medicines for Europe has called on the European Commission to urgently establish a “structured dialog” involving industry stakeholders, to help plan for an extended outbreak of coronavirus.

You may also be interested in...



EU Rips Up Competition Rulebook To Allow Collaboration On Coronavirus

A temporary framework has been adopted by the European Commission that will allow companies and associations to co-ordinate efforts to tackle the coronavirus pandemic without raising competition concerns. The move has been welcomed by the European off-patent industry.

EU Rips Up Competition Rulebook To Allow Collaboration On Coronavirus

A temporary framework has been adopted by the European Commission that will allow companies and associations to co-ordinate efforts to tackle the coronavirus pandemic without raising competition concerns. The move has been welcomed by the European off-patent industry.

EU Must Plan For Demand Spikes Amid Coronavirus

Stakeholders across the European medicines industry must co-ordinate to plan for increases in demand as the region continues to grapple with the coronavirus outbreak, off-patent industry association Medicines for Europe has insisted.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

GB149694

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel